The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

Other (Specify)

4.00

1. Issuer's Identity

**DELAWARE** 

CIK (Filer ID Number)

Previous
Names

None

Entity Type

0001479419 Hanes Newco, Inc. X Corporation

Name of Issuer

Limited Partnership

Kala Pharmaceuticals, Inc.

Limited Liability Company

Jurisdiction ofGeneral PartnershipIncorporation/OrganizationBusiness Trust

Year of Incorporation/Organization

Over Five Years Ago

X Within Last Five Years (Specify Year) 2009

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Kala Pharmaceuticals, Inc.

Street Address 1 Street Address 2

135 BEAVER STREET Suite 309

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

WALTHAM MASSACHUSETTS 02452 617-542-2241

3. Related Persons

Last Name First Name Middle Name

Paull Robert

Street Address 1 Street Address 2

135 Beaver Street Suite 309

City State/Province/Country ZIP/PostalCode

Waltham MASSACHUSETTS 02452

**Relationship:** X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Bitterman Kevin

Street Address 1 Street Address 2

135 Beaver Street Suite 309

City State/Province/Country ZIP/PostalCode

Waltham MASSACHUSETTS 02452

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Tepper Robert

Street Address 1 Street Address 2
135 Beaver Street Suite 309

City State/Province/Country ZIP/PostalCode

Waltham MASSACHUSETTS 02452

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Hanes Justin

Street Address 1 Street Address 2

135 Beaver Street Suite 309

City State/Province/Country ZIP/PostalCode

Waltham MASSACHUSETTS 02452

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Langer Robert

Street Address 1 Street Address 2

135 Beaver Street Suite 309

City State/Province/Country ZIP/PostalCode

Waltham MASSACHUSETTS 02452

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Courossi Peter

Street Address 1 Street Address 2

135 Beaver Street Suite 309

City State/Province/Country ZIP/PostalCode

Waltham MASSACHUSETTS 02452

**Relationship:** X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Pojasek Kevin

Street Address 1 Street Address 2

135 Beaver Street Suite 309

City State/Province/Country ZIP/PostalCode

Waltham MASSACHUSETTS 02452

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Chen Hongming

Street Address 1 Street Address 2

135 Beaver Street Suite 309

City State/Province/Country ZIP/PostalCode

Waltham MASSACHUSETTS 02452

**Relationship:** X Executive Officer Director

Clarification of Response (if Necessary):

## 4. Industry Group

Agriculture Banking & Financial Services

Commercial Banking

Insurance Investing

**Investment Banking** Pooled Investment Fund

Is the issuer registered as an investment company under

the Investment Company Act of 1940?

Yes

No

Other Banking & Financial Services

**Business Services** 

Energy

Coal Mining

**Electric Utilities** 

**Energy Conservation** 

**Environmental Services** 

Oil & Gas

Other Energy

Health Care

X Biotechnology

Health Insurance Hospitals & Physicians

Pharmaceuticals Other Health Care

Manufacturing

Real Estate

Commercial

Construction

**REITS & Finance** 

Residential

Other Real Estate

Retailing

Restaurants

Technology

Computers

Telecommunications

Other Technology

Travel

Airlines & Airports

Lodging & Conventions

Tourism & Travel Services

Other Travel

Other

## 5. Issuer Size

| Revenue Range                   | OR | Aggregate Net Asset Value Range |
|---------------------------------|----|---------------------------------|
| No Revenues                     |    | No Aggregate Net Asset Value    |
| \$1 - \$1,000,000               |    | \$1 - \$5,000,000               |
| \$1,000,001 - \$5,000,000       |    | \$5,000,001 - \$25,000,000      |
| \$5,000,001 -<br>\$25,000,000   |    | \$25,000,001 - \$50,000,000     |
| \$25,000,001 -<br>\$100,000,000 |    | \$50,000,001 - \$100,000,000    |
| Over \$100,000,000              |    | Over \$100,000,000              |
| X Decline to Disclose           |    | Decline to Disclose             |
| Not Applicable                  |    | Not Applicable                  |

## 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

| Rule 504(b)(1) (not (i), (ii) or (iii)) | Rule 505                    |
|---|-----------------------------|
| Rule 504 (b)(1)(i)                      | X Rule 506                  |
| Rule 504 (b)(1)(ii)                     | Securities Act Section 4(5) |
| Rule 504 (b)(1)(iii)                    | Investment Company Act Se   |

Investment Company Act Section 3(c)

Section 3(c)(1) Section 3(c)(9)Section 3(c)(2)Section 3(c)(10)Section 3(c)(3)Section 3(c)(11)Section 3(c)(4) Section 3(c)(12)Section 3(c)(5)Section 3(c)(13) Section 3(c)(6) Section 3(c)(14)

| 7. | Type | of | Fi | ling |
|----|------|----|----|------|
|    |      |    |    |      |

X New Notice Date of First Sale 2012-02-29 First Sale Yet to Occur Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity **Pooled Investment Fund Interests** Debt Tenant-in-Common Securities Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities

Security to be Acquired Upon Exercise of Option, Warrant or

Other Right to Acquire Security

Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as Yes X No a merger, acquisition or exchange offer?

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient Recipient CRD Number X None

(Associated) Broker or Dealer CRD X None (Associated) Broker or Dealer X None

Number

**Street Address 1 Street Address 2** 

ZIP/Postal City State/Province/Country Code

State(s) of Solicitation (select all that apply) All Check "All Statesâ€∏ or check individual Foreign/non-US States

13. Offering and Sales Amounts

**Total Offering Amount** \$7,243,205 USD or Indefinite

\$7,243,205 USD Total Amount Sold

\$0 USD or Indefinite Total Remaining to be Sold

Clarification of Response (if Necessary):

14. Investors

States

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

10

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

#### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

| Issuer                        | Signature         | Name of Signer | Title   | Date       |
|-------------------------------|-------------------|----------------|---|------------|
| Kala Pharmaceuticals,<br>Inc. | /s/ Kevin Pojasek | Kevin Pojasek  | Secretary and Vice President, Corporate Development | 2012-03-02 |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.